Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Melanoma-associated antigen D4 (MAGED4B)
- Target
- MAGED4B
- Molecular classification
- MAGE (Melanoma-associated antigen) family, Tumor-associated antigen, Protein-coding gene, Other (E3 ubiquitin ligase regulator)
01
Overview
Melanoma-associated antigen D4 (MAGED4B) is a member of the MAGE family of tumor-associated antigens. It is encoded by the *MAGED4B* gene on chromosome Xp11 and is primarily expressed in the brain and ovary under physiologic conditions, but overexpressed in several cancers, including glioma and oral squamous cell carcinoma. MAGED4B can promote tumor cell growth and migration, and its immunogenic peptides can elicit robust cytotoxic T cell responses, making it an attractive target for cancer immunotherapy. It also interacts with E3 ubiquitin ligases, potentially influencing protein degradation pathways and cell cycle regulation
- Other names
- MAGED4BMAGE family member D4BMAGE-D4 antigenMAGE-E1 antigen
02
Mechanism of action
Peptide vaccines stimulate antigen-specific cytotoxic T cell responses that target and kill MAGED4B-expressing tumor cells
03
Biological functions
Immune response: Tumor antigen that can elicit cytotoxic T cell responsesCell proliferation: Promotes tumor growth and migration in cancer cellsUbiquitin ligase regulation: May enhance E3 ubiquitin ligase activity, influencing protein turnover
04
Disease associations
Cancer (notably glioma and oral squamous cell carcinoma, and implicated in other solid tumors)Other (may have roles in cell cycle regulation and apoptosis)
05
Safety considerations
MAGED4B is not expressed in most normal tissues except for brain and ovary, which suggests a favorable safety profile for targeting, but off-target effects in these tissues must be considered
06
Interacting drugs
No specific approved drugs are listed that directly target MAGED4B, but several peptide vaccines under investigation use MAGED4B-derived immunogenic peptides
07
Biomarkers
MAGED4B expression levels may serve as tumor biomarkers for disease prognosis and patient selection in glioma and oral squamous cell carcinoma
Beyond the preview
Go deeper on Melanoma-associated antigen D4 (MAGED4B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Melanoma-associated antigen D4 (MAGED4B).